It is possible to increase the potency of T-cell-mediated anti-tumor effects by targeting FAPα, and combination of a dual-targeting vaccine with doxorubicin effectively increased the anti-tumor activity of the vaccine by decreasing immunosuppressive factors and promoting the infiltration of tumor cells by lymphocytes; this finding may provide useful guidance for clinical research on the combination of DNA vaccination with low-dose chemotherapy (170). This evidence concerns the gene FAP and neoplasm.